Market open
Vera Therapeutics/$VERA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vera Therapeutics
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Ticker
$VERA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
152
ISIN
US92337R1014
Website
VERA Metrics
BasicAdvanced
$1.4B
-
-$3.00
1.28
-
Price and volume
Market cap
$1.4B
Beta
1.28
52-week high
$49.23
52-week low
$18.53
Average daily volume
1.2M
Financial strength
Current ratio
27.682
Quick ratio
27.104
Long term debt to equity
9.958
Total debt to equity
10.18
Interest coverage (TTM)
-25.73%
Management effectiveness
Return on assets (TTM)
-23.46%
Return on equity (TTM)
-39.49%
Valuation
Price to book
2.52
Price to tangible book (TTM)
2.52
Price to free cash flow (TTM)
-7.925
Growth
Earnings per share change (TTM)
46.40%
3-year earnings per share growth (CAGR)
8.95%
What the Analysts think about VERA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Vera Therapeutics stock.
VERA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
VERA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
VERA News
AllArticlesVideos
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·6 days ago
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
GlobeNewsWire·1 week ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Vera Therapeutics stock?
Vera Therapeutics (VERA) has a market cap of $1.4B as of May 15, 2025.
What is the P/E ratio for Vera Therapeutics stock?
The price to earnings (P/E) ratio for Vera Therapeutics (VERA) stock is 0 as of May 15, 2025.
Does Vera Therapeutics stock pay dividends?
No, Vera Therapeutics (VERA) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Vera Therapeutics dividend payment date?
Vera Therapeutics (VERA) stock does not pay dividends to its shareholders.
What is the beta indicator for Vera Therapeutics?
Vera Therapeutics (VERA) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.